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Background
Recent studies have reported that the clinical benefit of
interleukin-2 (IL-2) immunotherapy for metastatic renal
cell carcinoma (mRCC) and melanoma (mM) may be
underestimated by typically reported outcomes, instead
suggesting that progression-free survival or “disease con-
trol rate” (DCR) may provide a more meaningful prognos-
tic indicator [1]. Therefore, we examined progression-free
survival to assess the clinical benefit of IL-2.
Methods
A total of 78 patients in Baton Rouge, Louisiana
enrolled in the PROCLAIM registry from 2011 to 2015
were reviewed, and 58 patients had complete survival
and response data. Patients received IL-2 600,000 IU/kg
intravenous boluses every 8 hours for up to 14 doses
(one cycle), up to 4 cycles. Using the Response Evalua-
tion Criteria in Solid Tumors v1.1, treatment response
was assessed as complete response (CR), partial response
(PR), stable disease (SD), or progressive disease (PD)
after cycle 2, cycle 4, and at each follow-up. Univariate
analysis of dichotomous or categorical predictors of sur-
vival was performed using the Kaplan-Meier method,
and differences were compared by the log-rank test
using Stata 12. Landmark analysis was conducted at 6-
month, 1-year, 2-year, and 3-year time points. A two-
tailed significance level of 0.05 was used to construct a
Cox proportional hazards regression model to obtain
hazard ratios (HR) for predictors of survival.
Results
To control for guarantee-time bias, the 6-month land-
mark from start of treatment was chosen, at which time
all patients had completed all cycles of IL-2. From the
6-month landmark, CR, PR, and SD did not reach med-
ian survival while PD had a 7.5 month median survival
(p=0.014). Differences in survival between DCR (Figure 1,
red line) and PD are significant (p=0.002) while differences
between ORR (Figure 2, red line) and non-objective
responders are not statistically significant (p=0.096). Num-
ber of doses (p=0.000; HR=0.891; 95% CI, 0.850 to 0.935)
and primary diagnosis of mRCC (p=0.004; HR=0.248; 95%
CI, 0.095 to 0.648) were significant covariates associated
with survival in the final Cox model.
Conclusions
Although our findings may have limited generalizability, in
this sample stable disease, a primary diagnosis of mRCC,
and the total number of IL-2 doses were significantly asso-
ciated with prolonged survival from the 6-month
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landmark. In addition to ORR, progression-free survival
should be reported to reflect the clinical benefit of IL-2
therapy.
Authors’ details
1Tulane University School of Medicine, New Orleans, LA, USA. 2Baton Rouge
General Internal Medicine Residency Program, Baton Rouge, LA, USA.
3Hematology/Oncology Clinic, Baton Rouge, LA, Baton Rouge, LA, USA.
4Baton Rouge General Medical Center Graduate Medical Education, Baton
Rouge, LA, USA.
Published: 4 November 2015
Reference
1. Hughes T, Klairmont M, Broucek J, Iodice G, Basu S, Kaufman HL: The
prognostic significance of stable disease following high-dose
interleukin-2 (IL-2) treatment in patients with metastatic melanoma and
renal cell carcinoma. Cancer Immunol Immunother 2015, 64(4):459-465.
doi:10.1186/2051-1426-3-S2-P138
Cite this article as: Kwan et al.: Stable disease, diagnosis and dose are
prognostic factors for survival after interleukin-2 immunotherapy.
Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P138.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Figure 2
Kwan et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P138
http://www.immunotherapyofcancer.org/content/3/S2/P138
Page 2 of 2
